We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Abbott Hits Sandoz With New Niaspan Patent Suit

Law360 (February 18, 2011, 1:43 PM EST) -- Abbott Laboratories has launched another patent infringement suit against Sandoz Inc. in an effort to keep a generic version of blockbuster cholesterol drug Niaspan off the market.

Mary B. Graham of Morris Nichols Arsht & Tunnell LLP lodged the suit on behalf of Abbott and its subsidiary Abbott Respiratory LLC in the U.S. District Court for the District of Delaware on Wednesday, accusing Sandoz of infringing Abbott's U.S. Patent Numbers 6,080,428 and 6,469,035.

The suit follows Sandoz's filing of an amended abbreviated new drug application with the U.S. Food and Drug Administration for approval to market 1000-, 750- and 500-milligram niacin...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS